Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism

Kuo Cheng Lu, Chin Feng Tseng, Chia Chao Wu, Lai King Yeung, Jin Shuen Chen, Tsu Yi Chao, Anthony J. Janckila, Lung T. Yam, Pauling Chu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background/Aims: Secondary hyperparathyroidism (SHP) is characterized by high bone turnover and elevated serum bone remodeling markers. Elevation of serum interleukin-6 (IL-6) levels is also characteristic of end-stage renal disease. This study investigates the effects of intravenous calcitriol on serum bone resorptive markers, namely, type 5b tartrate-resistant acid phosphatase (TRACP5b) and IL-6 in patients with SHP. Methods: Intravenous calcitriol therapy was given for 16 weeks to 24 patients on maintenance hemodialysis with plasma intact parathyroid hormone (iPTH) levels >300 pg/ml. Blood was drawn at baseline and every 4 weeks for 16 weeks for determination of the levels of biochemical parameters, iPTH, IL-6 and bone remodeling markers, including bone-specific alkaline phosphatase (bAP) and TRACP5b. Results: Only 21 patients responded to the calcitriol therapy, with significant decrements in serum iPTH after 4 weeks of therapy and thereafter. After 16 weeks of calcitriol therapy, 21 patients had significant decrements in serum iPTH (707.9 ± 317.8 vs. 205.0 ± 63.1 pg/ml, p <0.01). Prior to treatment, a significant correlation was found between increased levels of serum iPTH and IL-6 levels (r = 0.45, p <0.05). After treatment, there was also a significant and parallel lowering of levels of serum iPTH, IL-6 (8.52 ± 3.59 vs. 7.24 ± 2.81 pg/ml, p <0.01), bAP (54.68 ± 36.17 vs. 24.55 ± 13.84 U/l, p <0.01) and TRACP5b (3.41 ± 1.89 vs. 1.80 ± 0.55 U/l, p <0.01). Our results additionally showed significant positive correlationsbetween baseline levels of serum IL-6 and those of iPTH, bAP and TRACP5b. After 16 weeks of calcitriol treatment, the correlation between IL-6 and iPTH levels lost significance but levels of serum IL-6, bAP and TRACP5b remained significantly correlated. Conclusions: Elevated levels of serum IL-6 and bone remodeling markers, namely, bAP and TRACP5b which are common features of SHP, are effectively suppressed by calcitriol therapy. This indicates that hyperparathyroidism not only accelerates bone remodeling but may also aggravate inflammation in patients on maintenance hemodialysis.

Original languageEnglish
Pages (from-to)423-430
Number of pages8
JournalBlood Purification
Volume24
Issue number5-6
DOIs
Publication statusPublished - Dec 2006
Externally publishedYes

Fingerprint

Secondary Hyperparathyroidism
Calcitriol
Interleukin-6
Parathyroid Hormone
Bone Remodeling
Serum
Alkaline Phosphatase
Bone and Bones
Therapeutics
Renal Dialysis
Maintenance
Tartrate-Resistant Acid Phosphatase
Hyperparathyroidism
Chronic Kidney Failure
Inflammation

Keywords

  • Alkaline phosphatase, bone-specific
  • Calcitriol
  • Hyperparathyroidism, secondary
  • Interleukin-6
  • Tartrate-resistant acid phosphatase

ASJC Scopus subject areas

  • Nephrology
  • Hematology

Cite this

Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism. / Lu, Kuo Cheng; Tseng, Chin Feng; Wu, Chia Chao; Yeung, Lai King; Chen, Jin Shuen; Chao, Tsu Yi; Janckila, Anthony J.; Yam, Lung T.; Chu, Pauling.

In: Blood Purification, Vol. 24, No. 5-6, 12.2006, p. 423-430.

Research output: Contribution to journalArticle

Lu, KC, Tseng, CF, Wu, CC, Yeung, LK, Chen, JS, Chao, TY, Janckila, AJ, Yam, LT & Chu, P 2006, 'Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism', Blood Purification, vol. 24, no. 5-6, pp. 423-430. https://doi.org/10.1159/000094899
Lu, Kuo Cheng ; Tseng, Chin Feng ; Wu, Chia Chao ; Yeung, Lai King ; Chen, Jin Shuen ; Chao, Tsu Yi ; Janckila, Anthony J. ; Yam, Lung T. ; Chu, Pauling. / Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism. In: Blood Purification. 2006 ; Vol. 24, No. 5-6. pp. 423-430.
@article{57023c2a34f846b5afc6ea8d65dadfa2,
title = "Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism",
abstract = "Background/Aims: Secondary hyperparathyroidism (SHP) is characterized by high bone turnover and elevated serum bone remodeling markers. Elevation of serum interleukin-6 (IL-6) levels is also characteristic of end-stage renal disease. This study investigates the effects of intravenous calcitriol on serum bone resorptive markers, namely, type 5b tartrate-resistant acid phosphatase (TRACP5b) and IL-6 in patients with SHP. Methods: Intravenous calcitriol therapy was given for 16 weeks to 24 patients on maintenance hemodialysis with plasma intact parathyroid hormone (iPTH) levels >300 pg/ml. Blood was drawn at baseline and every 4 weeks for 16 weeks for determination of the levels of biochemical parameters, iPTH, IL-6 and bone remodeling markers, including bone-specific alkaline phosphatase (bAP) and TRACP5b. Results: Only 21 patients responded to the calcitriol therapy, with significant decrements in serum iPTH after 4 weeks of therapy and thereafter. After 16 weeks of calcitriol therapy, 21 patients had significant decrements in serum iPTH (707.9 ± 317.8 vs. 205.0 ± 63.1 pg/ml, p <0.01). Prior to treatment, a significant correlation was found between increased levels of serum iPTH and IL-6 levels (r = 0.45, p <0.05). After treatment, there was also a significant and parallel lowering of levels of serum iPTH, IL-6 (8.52 ± 3.59 vs. 7.24 ± 2.81 pg/ml, p <0.01), bAP (54.68 ± 36.17 vs. 24.55 ± 13.84 U/l, p <0.01) and TRACP5b (3.41 ± 1.89 vs. 1.80 ± 0.55 U/l, p <0.01). Our results additionally showed significant positive correlationsbetween baseline levels of serum IL-6 and those of iPTH, bAP and TRACP5b. After 16 weeks of calcitriol treatment, the correlation between IL-6 and iPTH levels lost significance but levels of serum IL-6, bAP and TRACP5b remained significantly correlated. Conclusions: Elevated levels of serum IL-6 and bone remodeling markers, namely, bAP and TRACP5b which are common features of SHP, are effectively suppressed by calcitriol therapy. This indicates that hyperparathyroidism not only accelerates bone remodeling but may also aggravate inflammation in patients on maintenance hemodialysis.",
keywords = "Alkaline phosphatase, bone-specific, Calcitriol, Hyperparathyroidism, secondary, Interleukin-6, Tartrate-resistant acid phosphatase",
author = "Lu, {Kuo Cheng} and Tseng, {Chin Feng} and Wu, {Chia Chao} and Yeung, {Lai King} and Chen, {Jin Shuen} and Chao, {Tsu Yi} and Janckila, {Anthony J.} and Yam, {Lung T.} and Pauling Chu",
year = "2006",
month = "12",
doi = "10.1159/000094899",
language = "English",
volume = "24",
pages = "423--430",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "S. Karger AG",
number = "5-6",

}

TY - JOUR

T1 - Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism

AU - Lu, Kuo Cheng

AU - Tseng, Chin Feng

AU - Wu, Chia Chao

AU - Yeung, Lai King

AU - Chen, Jin Shuen

AU - Chao, Tsu Yi

AU - Janckila, Anthony J.

AU - Yam, Lung T.

AU - Chu, Pauling

PY - 2006/12

Y1 - 2006/12

N2 - Background/Aims: Secondary hyperparathyroidism (SHP) is characterized by high bone turnover and elevated serum bone remodeling markers. Elevation of serum interleukin-6 (IL-6) levels is also characteristic of end-stage renal disease. This study investigates the effects of intravenous calcitriol on serum bone resorptive markers, namely, type 5b tartrate-resistant acid phosphatase (TRACP5b) and IL-6 in patients with SHP. Methods: Intravenous calcitriol therapy was given for 16 weeks to 24 patients on maintenance hemodialysis with plasma intact parathyroid hormone (iPTH) levels >300 pg/ml. Blood was drawn at baseline and every 4 weeks for 16 weeks for determination of the levels of biochemical parameters, iPTH, IL-6 and bone remodeling markers, including bone-specific alkaline phosphatase (bAP) and TRACP5b. Results: Only 21 patients responded to the calcitriol therapy, with significant decrements in serum iPTH after 4 weeks of therapy and thereafter. After 16 weeks of calcitriol therapy, 21 patients had significant decrements in serum iPTH (707.9 ± 317.8 vs. 205.0 ± 63.1 pg/ml, p <0.01). Prior to treatment, a significant correlation was found between increased levels of serum iPTH and IL-6 levels (r = 0.45, p <0.05). After treatment, there was also a significant and parallel lowering of levels of serum iPTH, IL-6 (8.52 ± 3.59 vs. 7.24 ± 2.81 pg/ml, p <0.01), bAP (54.68 ± 36.17 vs. 24.55 ± 13.84 U/l, p <0.01) and TRACP5b (3.41 ± 1.89 vs. 1.80 ± 0.55 U/l, p <0.01). Our results additionally showed significant positive correlationsbetween baseline levels of serum IL-6 and those of iPTH, bAP and TRACP5b. After 16 weeks of calcitriol treatment, the correlation between IL-6 and iPTH levels lost significance but levels of serum IL-6, bAP and TRACP5b remained significantly correlated. Conclusions: Elevated levels of serum IL-6 and bone remodeling markers, namely, bAP and TRACP5b which are common features of SHP, are effectively suppressed by calcitriol therapy. This indicates that hyperparathyroidism not only accelerates bone remodeling but may also aggravate inflammation in patients on maintenance hemodialysis.

AB - Background/Aims: Secondary hyperparathyroidism (SHP) is characterized by high bone turnover and elevated serum bone remodeling markers. Elevation of serum interleukin-6 (IL-6) levels is also characteristic of end-stage renal disease. This study investigates the effects of intravenous calcitriol on serum bone resorptive markers, namely, type 5b tartrate-resistant acid phosphatase (TRACP5b) and IL-6 in patients with SHP. Methods: Intravenous calcitriol therapy was given for 16 weeks to 24 patients on maintenance hemodialysis with plasma intact parathyroid hormone (iPTH) levels >300 pg/ml. Blood was drawn at baseline and every 4 weeks for 16 weeks for determination of the levels of biochemical parameters, iPTH, IL-6 and bone remodeling markers, including bone-specific alkaline phosphatase (bAP) and TRACP5b. Results: Only 21 patients responded to the calcitriol therapy, with significant decrements in serum iPTH after 4 weeks of therapy and thereafter. After 16 weeks of calcitriol therapy, 21 patients had significant decrements in serum iPTH (707.9 ± 317.8 vs. 205.0 ± 63.1 pg/ml, p <0.01). Prior to treatment, a significant correlation was found between increased levels of serum iPTH and IL-6 levels (r = 0.45, p <0.05). After treatment, there was also a significant and parallel lowering of levels of serum iPTH, IL-6 (8.52 ± 3.59 vs. 7.24 ± 2.81 pg/ml, p <0.01), bAP (54.68 ± 36.17 vs. 24.55 ± 13.84 U/l, p <0.01) and TRACP5b (3.41 ± 1.89 vs. 1.80 ± 0.55 U/l, p <0.01). Our results additionally showed significant positive correlationsbetween baseline levels of serum IL-6 and those of iPTH, bAP and TRACP5b. After 16 weeks of calcitriol treatment, the correlation between IL-6 and iPTH levels lost significance but levels of serum IL-6, bAP and TRACP5b remained significantly correlated. Conclusions: Elevated levels of serum IL-6 and bone remodeling markers, namely, bAP and TRACP5b which are common features of SHP, are effectively suppressed by calcitriol therapy. This indicates that hyperparathyroidism not only accelerates bone remodeling but may also aggravate inflammation in patients on maintenance hemodialysis.

KW - Alkaline phosphatase, bone-specific

KW - Calcitriol

KW - Hyperparathyroidism, secondary

KW - Interleukin-6

KW - Tartrate-resistant acid phosphatase

UR - http://www.scopus.com/inward/record.url?scp=33845921650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845921650&partnerID=8YFLogxK

U2 - 10.1159/000094899

DO - 10.1159/000094899

M3 - Article

C2 - 16888370

AN - SCOPUS:33845921650

VL - 24

SP - 423

EP - 430

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

IS - 5-6

ER -